Building an Integrated Biopharma Company: Crucell (B) Harvard Case Solution & Analysis

The Crucell (B) scenario revise events at Crucell from 2009. In September, 2009, Johnson & Johnson purchased 18% of Crucell for $400 million.

This investment was an essential part of a business development deal. Later, in 2012, Johnson & Johnson purchased Crucell for $2.8 billion.

PUBLICATION DATE: February 25, 2015 PRODUCT #: 815086-HCB-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

Related Case Solutions & Analyses:

ABN-AMRO Holding N.V. and Smit Transformatoren N.V. (C) Australia in the 1990s: Lucky or Broke Supplement Star Cablevision Group (B): Adjusting to a Stock Market Correction Germany in the 1990s: Managing Reunification Supplement ACP Inc. B Immigration Policy in Germany European Airline Industry, 1993 – 2009: Flying into Turbulence (A) Foxconn V BYD (B): Strategic Approach to Intellectual Property Management in Emerging Markets Psaltry International Ltd: Challenges Refining Cassava Starch in Rural Nigeria Strategy Execution Module 9: Building a Balanced Scorecard